Drug intelligence / Profile preview

BM-Allo.MSC

Development stage: Unknown
Lead developer: ImmunityBio
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intradiscal

Overview

BM-Allo.MSC is an allogeneic, bone marrow-derived mesenchymal stem cell (MSC) therapy developed by NantKwest (now part of ImmunityBio) for the treatment of acute respiratory distress syndrome (ARDS), particularly in patients with severe COVID-19. The therapy leverages the immunomodulatory properties of MSCs to reduce systemic inflammation and mitigate lung injury. It was evaluated in a Phase 1b randomized, double-blind, placebo-controlled clinical trial (NCT04616482) to assess safety and preliminary efficacy in patients requiring mechanical ventilation. The donor material for the therapy was sourced through a partnership with Be The Match BioTherapies (National Marrow Donor Program).

Other names: allogeneic bone marrow-derived mesenchymal stem cellsNantKwest MSC

Beyond the preview

Go deeper on BM-Allo.MSC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM-Allo.MSC.

Explore the full profile